Volume 28, Number 9—September 2022
Research
Rapid Adaptation of Established High-Throughput Molecular Testing Infrastructure for Monkeypox Virus Detection
Dominik Nörz, Hui Ting Tang, Petra Emmerich, Katja Giersch, Nicole Fischer, Stephan Schmiedel, Marylyn M. Addo, Martin Aepfelbacher, Susanne Pfefferle, and Marc Lütgehetmann
Table 3
Hit rates during limit of detection studies of dual-target MPXV assay rapidly adapted from established high-throughput molecular testing infrastructure*
| Concentration, copies/mL | NVAR | MPXV | Overall |
|---|---|---|---|
| 100 | 21/21 | 21/21 | 21/21 |
| 50 | 21/21 | 21/21 | 21/21 |
| 25 | 21/21 | 21/21 | 21/21 |
| 12.5 | 20/21 | 21/21 | 21/21 |
| 6.25 | 19/21 | 20/21 | 21/21 |
| 3.125 | 11/21 | 13/21 | 15/21 |
| 1.56 | 11/21 | 11/21 | 17/21 |
| 0.78 | 3/21 | 6/21 | 7/21 |
*Results represent no. positive/no. tested. Limits of detection were determined by serial dilution of a quantified MPXV standard (quantified by digital PCR) as a reference. Concentrations represent copies/mL of specimen. Dilution series were generated automatically using a STARlet Liquid Handler (Hamilton, https://www.hamiltoncompany.com). We calculated 95% probability of detection by using MedCalc statistical software (https://www.medcalc.org). MPXV, monkeypox virus; NVAR, nonvariola orthopoxvirus.
Page created: July 13, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.